The Phase III trial follows the company’s previous Phase I trial, which saw 12 participants dosed with Bemdaneprocel. Credit: Shutterstock / Yuri A US-based Bayer subsidiary BlueRock Therapeutics has ...
Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.
Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310.
The Dutch device firm is touting the results of its sleep diagnostic trials finding its sleep device comparable with in-lab tests.
The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.
There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge in ...
Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.
There is a significant discourse in the literature when estimating clinical trial costs due to the lack of transparency throughout the industry regarding the true expense of bringing a drug from bench ...
HMNC has completed the subject randomisation in its Phase IIb OLIVE trial of BH-200 for major depressive disorder (MDD) treatment.
MaaT Pharma has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.
The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...